Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn's Disease: results from the U-ENDURE long-term extension

被引：0

作者：

D'Haens, G. ^{[1
]}

Louise, E. ^{[2
]}

Loftus, E. V., Jr. ^{[3
]}

Regueiro, M. ^{[4
]}

Jairath, V. ^{[5
]}

Magro, F. ^{[6
,7
]}

Nakase, H. ^{[8
]}

Dubcenco, E. ^{[9
]}

Lacerda, A. P. ^{[9
]}

Feng, T. ^{[9
]}

Duncan, B. ^{[9
]}

Wang, T. ^{[9
]}

Ford, S. ^{[9
]}

Anyanwu, S. I. ^{[9
]}

Juilleratm, P. ^{[10
,11
,12
]}

Blumenstein, I. ^{[13
]}

机构：

[1] Amsterdam Univ Med Ctr, Amsterdam, Netherlands

[2] Hosp CHU Liege, Liege, Belgium

[3] Mayo Clin, Coll Med & Sci, Rochester, MN USA

[4] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[5] Western Univ, London, ON, Canada

[6] Univ Porto, Porto, Portugal

[7] Sao Joao Univ Hosp Ctr, Porto, Portugal

[8] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan

[9] AbbVie Inc, N Chicago, IL USA

[10] Intesto Crohn & Colitis Ctr, Bern, Switzerland

[11] Intesto Crohn & Colitis Ctr, Fribourg, Switzerland

[12] Bern Univ Hosp, Visceral Surg & Med, Bern, Switzerland

[13] Goethe Univ Hosp, Frankfurt, Germany

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IBD-2

引用

页码：2S / 2S

页数：1